- Home
- OCS vs GHRS Comparison
OCS vs GHRS Comparison
Compare OCS & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCS
- GHRS
- Stock Information
- Founded
- OCS 2003
- GHRS 2018
- Country
- OCS Switzerland
- GHRS Ireland
- Employees
- OCS N/A
- GHRS N/A
- Industry
- OCS Biotechnology: Pharmaceutical Preparations
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- OCS Health Care
- GHRS Health Care
- Exchange
- OCS Nasdaq
- GHRS Nasdaq
- Market Cap
- OCS 956.4M
- GHRS 960.2M
- IPO Year
- OCS N/A
- GHRS 2021
- Fundamental
- Price
- OCS $17.64
- GHRS $14.36
- Analyst Decision
- OCS Strong Buy
- GHRS Strong Buy
- Analyst Count
- OCS 3
- GHRS 8
- Target Price
- OCS $35.33
- GHRS $30.63
- AVG Volume (30 Days)
- OCS 13.6K
- GHRS 352.7K
- Earning Date
- OCS 08-26-2025
- GHRS 09-02-2025
- Dividend Yield
- OCS N/A
- GHRS N/A
- EPS Growth
- OCS N/A
- GHRS N/A
- EPS
- OCS N/A
- GHRS N/A
- Revenue
- OCS $847,333.00
- GHRS N/A
- Revenue This Year
- OCS $10.23
- GHRS N/A
- Revenue Next Year
- OCS $912.87
- GHRS N/A
- P/E Ratio
- OCS N/A
- GHRS N/A
- Revenue Growth
- OCS N/A
- GHRS N/A
- 52 Week Low
- OCS $10.79
- GHRS $6.00
- 52 Week High
- OCS $23.08
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- OCS 40.60
- GHRS 47.65
- Support Level
- OCS $17.27
- GHRS $12.81
- Resistance Level
- OCS $18.57
- GHRS $15.28
- Average True Range (ATR)
- OCS 0.53
- GHRS 1.52
- MACD
- OCS 0.01
- GHRS -0.40
- Stochastic Oscillator
- OCS 31.11
- GHRS 23.13
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.